14.01

5.40% -0.80

After Hours: 14.22 0.21 +1.50%

Kalvista Pharmaceuticals Inc (KALV)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Kalvista Pharmaceuticals Inc stock is traded at $14.01, with a volume of 2.23M. It is down -5.40% in the last 24 hours and up +14.37% over the past month. KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Previous Close:

$14.81

Open:

$14.61

24h Volume:

2.23M

Relative Volume:

1.74

Market Cap:

$705.26M

Revenue:

Net Income/Loss:

$-156.39M

P/E Ratio:

-3.7967

EPS:

-3.69

Net Cash Flow:

$-123.06M

1W Performance:

-11.44%

1M Performance:

+14.37%

6M Performance:

+12.53%

1Y Performance:

+33.94%

1-Day Range:

$13.44

$14.89

1-Week Range:

$13.26

$17.28

52-Week Range:

$7.30

$17.28

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Name

Kalvista Pharmaceuticals Inc

Sector

Healthcare (1152)

Industry

Biotechnology (648)

Phone

(857) 999-0075

Address

200 CROSSING BOULEVARD, FRAMINGHAM, MA

Employee

270

Twitter

@kalvista

Next Earnings Date

2025-09-11

Latest SEC Filings

KALV's Discussions on Twitter

Compare KALV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KALV Kalvista Pharmaceuticals Inc	14.01	774.73M	0	-156.39M	-123.06M	-3.69
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-31-25	Initiated	JMP Securities	Mkt Outperform
Jan-07-25	Initiated	TD Cowen	Buy
Dec-18-24	Initiated	BofA Securities	Buy
Jun-15-20	Initiated	H.C. Wainwright	Buy
Jul-29-19	Initiated	SVB Leerink	Outperform
Mar-20-19	Initiated	Needham	Buy
Oct-30-18	Initiated	Jefferies	Buy
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Aug-31-17	Initiated	BTIG Research	Buy

View All

Kalvista Pharmaceuticals Inc Stock (KALV) Latest News

Sep 12, 2025

Kalvista stock price target raised to $28 from $27 at JMP on strong Ekterly demand - Investing.com UK

Sep 12, 2025

KalVista Pharmaceuticals (KALV) Maintains 'Buy' Rating by Needham | KALV Stock News - GuruFocus

Sep 12, 2025

KalVista Pharmaceuticals (KALV) Target Price Raised by JMP Securities | KALV Stock News - GuruFocus

Sep 12, 2025

KalVista reports strong sales in early launch of hereditary angioedema drug - Endpoints News

Sep 12, 2025